Objective: The learning system "KimBen pharma" was introduced into pharmacy education at Okayama University to improve the quality of pharmacy education in accordance with the revision of the Model Core Curriculum for Pharmacy Education.Methods: In this study, we conducted a questionnaire survey of third- to fifth-year pharmacy students as of 2023 to investigate their satisfaction with the learning system and survey on students' awareness following its introduction.Results: Overall, 79% of the students accorded a score of 4 or higher for the item "satisfaction with using KimBen pharma." In addition, 95.2 and 91.9% of the students scored 4 or higher in the "I could feel the clinical pharmacist's point of view" and "I could imagine that what I learned at the university would be useful in the clinical setting" sections, respectively.Conclusion: Pharmacy education using KimBen pharma is highly satisfactory for students, and the system is considered a desirable educational tool across all grade levels from third to fifth year. Additionally, "KimBen pharma" helps students understand the perspective of pharmacists in clinical settings and assists them in concretely visualizing how the content learned at university can be applied in real-world clinical practice.

Objective: To prevent the mis-prescription of drugs that differs from the true intention, it is important to understand the factors underlying mis-prescription. In this study, we focused on drug prescription errors caused by drug name similarities and compared drug dispensing errors by pharmacists to clarify their characteristics.Methods: We extracted cases of drug prescription and dispensing errors caused by drug name similarity from "near-miss events from pharmacies" reported from March 2020 to October 2022, which were curated by the Japan Council for Quality Health Care. By comparing the characteristics of pairs of "drugs intended to be prescribed or dispensed" and "drugs that were mis-prescribed or misdispensed" (called as drug name pairs), we analyzed trends in drug prescription errors caused by drug name similarity. Specifically, we evaluated drug name similarity (calculated using m2-Visually Weighted Head and Tail-weighted Fragmentary Pattern-Based Measure; m2-vwhtfrag), the number of initial common characters, and drug efficacy similarity (evaluated by drug efficacy classification number) in drug name pairs and assessed their occurrence among drug prescribing and dispensing error cases.Results: From the "near-miss events from pharmacies," 234 cases of prescription errors and 152 cases of dispensing errors caused by drug name similarity were extracted. Drug prescription errors exhibited higher drug name similarity (i.e., higher values of m2-vwhtfrag) and more initial common characteristics than drug dispensing errors. In contrast, drug prescription errors showed a lower consistency in drug efficacy similarity.Conclusion: In this study, we found that prescription errors by physicians were more likely to be influenced by drug name similarity and less likely to be influenced by drug efficacy similarity compared to the dispensing errors by pharmacists. These findings are reasonable, considering the characteristics of the prescription ordering systems.

Background: This study surveyed pharmacists registered with the Yamaguchi Prefectural Pharmacists Association to determine the key elements of tablet printing design that enhance visibility and distinguishability during dispensing.Objectives: The purpose of this study is to identify suitable design components for tablets that enhance visibility and distinguishability by utilizing text data.Methods: Given the high risk of medication errors due to similar-looking tablets, the study employed KH Coder for text mining analysis of free-text responses.Results: Results indicated that design elements such as "horizontal writing," "straight lines, " and "emphasis on characters" significantly improve visibility and distinguishability, particularly for similar-looking tablets. The findings from this study provide specific guidelines for optimal tablet design, aiming to improve pharmacists' efficiency and enhance medication safety.Conclusions: KH Coder proved to be a valuable tool for analyzing qualitative data in the medical field. While the study focused on pharmacists in Yamaguchi Prefecture, expanding the survey to a national scale is recommended to validate and generalize the findings. This research supports the development of standardized tablet designs that can minimize dispensing errors and ensure patient safety, highlighting the importance of effective tablet printing design in pharmaceutical practice.

Objective: Of the total number of prescriptions received, the percentage of refill prescriptions in May-June 2022 was 0.053%. In order to speculate on the reasons for the low utilization rate of the refill system and future developments, we surveyed patients who have been receiving continuous drug treatment for more than 6 months to determine their attitudes toward the refill system.Methods: The survey was conducted on the Web and valid responses were obtained from 290 respondents.Results: The respondents were 44.8% male and 55.2% female, with a mean age of 45.6 ± 10.5 years. Respondents' diseases included hypertension (32.1%), dyslipidemia (15.9%), diabetes (15.2%), psychiatric diseases (10.0%), skin diseases (9.3%), and others. Of the respondents, 83.4% had no prescription change within 6 months, and 69.0% had access to treatment medications for the purpose of going to the hospital, indicating that their symptoms were stable and they could use the refill system. In addition, we found that only 17.2% were aware of the refill system. However, 73.4% of respondents indicated their intention to use the refill system in the future. Therefore, our results strongly suggest that the reason for the lack of its use is due to a lack of awareness of it.Conclusion: It is expected that the refill system will be promoted in the future through awareness-raising events and education of the public. It is thought that the use of the refill system may cause delays in the detection of adverse drug reactions and the overlooking of worsening health conditions. The issue is whether pharmacists can appropriately judge whether or not to continue refill prescriptions.

Objective: The Immunization Health Damage Relief Program was established to provide "prompt and wide-ranging" relief for health damage caused by routine vaccination.Methods: In this study, utilizing the report of the Subcommittee on Infectious Diseases and Immunization, we investigated the relief status of persons who received the new coronavirus vaccine. The study period was three years, from 2021 to 2023, and the number of cases accepted, the number of certifications, the number of denials, and the number of delays were analyzed.Results: Most of the claims were for medical expenses and medical benefits, and the remaining claims were for lump-sum death benefits and funeral expenses. The approval rate was 84.9%, and the denial rate was 14.1%. The scrutiny rate was less than 30% since July 2022, but with the establishment of a new study group on January 2023, the rate rose to approximately 70%. Initially, none of the lump-sum death payments were approved, but later the approval rate increased, and there was a period when almost all the lump-sum death payments were approved.Conclusions: The Ministry of Health, Labor and Welfare (MHLW) is responding as quickly as possible to the increasing number of applications, but the number of health relief applications is unprecedented in the history of vaccines. For the victims and their families, the situation does not appear to be satisfactory.

Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are widely used for diabetes, chronic heart failure, and chronic kidney disease. However, the incidence of volume depletion in patients when pharmacists implement risk-minimization strategies is unknown. Risk factors for volume depletion requiring further treatment have not been investigated in detail. Therefore, we retrospectively investigated the occurrence and risk factors of volume depletion in patients taking SGLT2i. Methods: This study included patients 18 years or older using SGLT2i between November 2014 and December 2021. Patients prescribed an SGLT2i at another hospital who were referred to our clinic where their initial SGLT2i prescription was a continuation prescription, patients who were referred to another medical institution during their 52-week follow-up, patients who discontinued their visits to our clinic or unknown reasons were excluded. The pharmacist provided patients with risk management plan literature at their first provision of an SGLT2 inhibitor. The endpoints were the rate of patients on SGLT2i who experienced volume depletion, rate of hospitalization to treat volume depletion, discontinuation rate, and risk factors. Results: SGLT2i caused volume depletion in 12 patients (0.5 %) and hospitalization in 1 patient (0.04 %), 83.3% of them occurred within 3 months after starting treatment. Risk factors for volume depletion were identified as age ≧ 75 years, renal dysfunction with eGFR less than 60 mL/min/1.73 m2, history of chronic heart failure, and chronic kidney disease. Conclusion: This study revealed risk factors associated with SGLT2i-induced volume depletion, but further investigation is required with an increased number of cases.

Objective: Contrast media side effects range from minor ones such as itching and vomiting to life-threatening ones such as hypotension and loss of consciousness. The purpose of this study was to determine how contrast media side effects are actually managed in hospitals nationwide, as well as to identify opportunities for the pharmacy department to be involved in contrast media administration, and pharmacists’ awareness of the risk of contrast media side effects. Methods: A self-administered, unmarked questionnaire survey was conducted in the pharmacy departments of 2,000 hospitals nationwide. The survey asked about the existence of internal rules and manuals regarding contrast media at each facility, how to deal with patients at risk for side effects, opportunities for intervention with patients by the pharmacy department, and opportunities for discussion among pharmacists and other professionals regarding the administration of contrast media. Results: Of the 2,000 facilities, 96 responded to the questionnaire, among which 69 had internal regulations or manuals. In those with manuals, the manuals stipulated measures such as not administering contrast media or administering premedication in the case of patients with a history of contrast media side effects. In facilities where the manual recommended premedication, it was found that premedication was administered in both inpatient and outpatient settings. Regarding the role of the pharmacy department, it was found that intervention in all items related to risk factors for adverse drug reactions was achieved for only about 10% of the outpatients. Conclusion: This study revealed that many facilities are involved in the management of contrast media side effects. The results indicate that there is scope for pharmacy departments to intervene more proactively in outpatient settings to ensure appropriate contrast media use in the future.

Objective: The coronavirus disease 2019 (COVID-19) vaccine was a specially approved pharmaceutical in Japan in February 2021. However, several people were concerned about its safety. Therefore, we conducted a survey on our hospital staff with suspected adverse effects related to COVID-19 vaccines and promptly published the results on our website. Methods: The current study included hospital staff who received the COVID-19 vaccine. A questionnaire survey on suspected adverse effects was conducted after each vaccination from the first to the fifth dose. Data on the survey results were promptly posted on the hospital’s website. The number of hits and time spent on the site were also evaluated. Then, we examined. the media (newspapers and television) that reported our findings and the content of their coverage. Results: There were no new findings regarding suspected adverse effects of the COVID-19 vaccines. An article published on our website on June 18, 2021, received more than 9,000 page views with an average time spent of > 3 min. Four media outlets reported on our hospital’s articles from June to July 2021, when public interest in the first and second doses of the vaccine was high. Conclusion: The early release of the survey results has provided a source of information for people who want to obtain safety information regarding the adverse effects of the COVID-19 vaccine.

Objective: Eye drops may contain certain preservatives, and there is concern in patients who use them on a daily basis for the treatment of diseases, including corneal epithelial disorder and glaucoma. PF eye drops (Rohto Nitten Co., Ltd.) are used widely; however, their usability may be difficult in patients prescribed these medications for the first time. Therefore, fact-finding was performed on the usability of PF eye drops, particularly the difficulty in squeezing out these eye drops. Methods: The squeezing forces for various eye drops in 11 different shapes were determined. A sensuality evaluation examination on “the easiness of pushing out the eye drops” was performed in addition to a questionnaire survey targeting patients who used eye drops at a community pharmacy. Results: The squeezing forces ranged from 2.0 to 17.1 N. This study showed that the squeezing force tended to increase as the drop got closer to the opening of the container. Significant differences in the sensuality examination scores were found: 3.09 points for Santen Pharmaceutical Co., Ltd.; 3.07 points for Senju Pharmaceutical Co., Ltd.; 2.47 points for Sawai Pharmaceutical Co., Ltd.; and 1.37 points for PF eye drops for any place other than Santen and Senju (p<0.001). Conclusion: When eye drops were prescribed for an elderly individual, the pharmacist considered it necessary to suggest an alternative agent to the doctor depending on body function. In addition, it is important to explain to the patient that an additional squeezing force is required to push out the drop as it gets closer to the opening of the container.

Objective: In Japan, pharmaceutical manufacturers have been required to develop a Risk Management Plan (RMP) since April 2013. Publication of the RMP is expected to enable the wide content-sharing of post-marketing risk management and its utilization among medical professionals to further enhance and strengthen post-marketing safety measures. In this study, we examined what points should be focused on for continuous utilization of RMPs after drug approvals by investigating the numbers of safety concerns addition of antineoplastic and immunomodulating agents, and where safety concerns added after approval are listed in package inserts. Furthermore, we investigated the reasons why these safety concerns were considered as such. Methods: Antineoplastics and immunomodulating agents, which account for more than half of all drugs containing new active ingredients approved in recent years, among drugs containing new active ingredients approved from fiscal year (FY) 2013 to FY 2019 were included in the study. The safety concerns (excluding important missing information) in RMPs as of April 1, 2021 for the subject drugs were compared with those at the time of approval. Safety concerns added after approval were investigated where they were listed in package inserts as of April 1, 2021. Furthermore, risks that were added as important potential risks were investigated as to why they were considered as such. Results: There were 117 risks added after approval. Those added to the important identified risks were listed in one of the sections of the package insert, whereas 11 risks were added to the important potential risks that could not be confirmed in the package inserts. Some important potential risks added after approval are suspected to have a causal relationship with the drug, but were not listed in the package inserts. Conclusion: It is important to utilize RMPs continuously to further understand risks of taking the drug.